论文部分内容阅读
目的探讨阿托伐他汀对心绞痛(UA)患者高敏C反应蛋白(hs-CRP)浓度的影响。方法将106例UA患者分为阿托伐他汀组和常规治疗组。阿托伐他汀组在常规治疗基础上加上阿托伐他汀,分别在1个月、2个月及3个月内测定hs-CRP水平及治疗前的基础水平。结果常规治疗组患者在治疗3个月时hs-CRP浓度逐渐降低,阿托伐他汀组在治疗1个月时开始下降,3个月明显下降,阿托伐他汀组患者治疗1个月和3个月时hs-CRP显著低于同期常规治疗组。结论阿托伐他汀可以在短时间内明显降低患者血清hs-CRP浓度。
Objective To investigate the effect of atorvastatin on the concentration of high-sensitivity C-reactive protein (hs-CRP) in patients with angina pectoris (UA). Methods 106 patients with UA were divided into atorvastatin group and conventional treatment group. Atorvastatin group plus atorvastatin on the basis of conventional treatment, respectively, at 1 month, 2 months and 3 months to determine hs-CRP levels and baseline levels before treatment. Results In the conventional treatment group, the hs-CRP concentration gradually decreased at 3 months of treatment, the atorvastatin group began to decline at 1 month and decreased significantly at 3 months, and the patients in the atorvastatin group treated for 1 month and 3 months Month hs-CRP was significantly lower than the same period conventional treatment group. Conclusions Atorvastatin can significantly reduce the serum hs-CRP level in patients in a short period of time.